Late Phase Drug Development World Americas 2012 - list of speakers 

Ms. Kushner’s professional research career has almost exclusively been in the area of late phase development. Following her nursing training, she joined the pharmaceutical industry as a Clinical Data Coordinator and enjoyed a variety of management positions in the late phase group of another large CRO. In these roles, she managed the data aspects...

Vipin Arora has over 17 years of Pharmaceutical Industry experience as lead Statistician, Manager, Group Head and Director in Analytical Sciences. Vipin has experience in developing strategies, in-licensing and out-licensing, pre-submission and follow up activities with Regulatory Agencies in North America, EU, Japan and other regions, approval...

As Director of Late Phase Solutions, Patrick assists global pharmaceutical, biotechnology and medical device companies utilize electronic data capture technology to address the challenges of post-approval studies. Prior to joining Medidata, Patrick founded Chassaigne & Associates, a management consulting company with a focus on increasing...

Dr. Reinerio A. Deza, currently Head of Pharmacovigilance at Cubist Pharmaceuticals, has over 20 years of experience in the pharmaceutical industry, primarily in Pharmacovigilance (PV) but has also included Medical Affairs. Most recently, Rene was at Merck (Schering-Plough) as the Sr. Director of Medical Services and the Clinical Risk Management...

Dr. Foegh brings to Agile's executive management team more than 20 years of experience in the pharmaceutical and biotechnology industries. She was most recently Vice President of Medical Affairs, Strategy & Development for Female Health Care at Berlex, Inc., where she was responsible for the successful development and regulatory approval of...

Dr. Weinong Guo is currently Senior Director & Program Section Leader, Cardiovascular Clinical Science Unit within the CVM Development Franchise at Novartis based in East Hanover, NJ where he is involved in designing and executing later clinical drug development programs targeting atherosclerosis, thrombosis and heart failure, etc. Dr. Guo is a...

2010- to date- Medical Director, Global Surveillance and Pharmacoepidemiology, Abbott Laboratories 2009-2010- Director, Epidemiology, Global Safety Surveillance and Epidemiology, Pfizer 2005-to 2009-Director, Epidemiology, Global Safety Surveillance and Epidemiology, Wyeth Pharmaceuticals 2000-2005- Associate Professor and Research...

Toshio Kimura is an Associate Director in Biostatistics at Boehringer Ingelheim Pharmaceuticals. He has worked extensively with PROs and ePROs in particular and has interacted with FDA divisions including the Study Endpoint and Label Development (SEALD). In his most recent NDA submission, ePRO was used to collect the primary endpoint. As part...

Dr. Maria Madison has been working in health research since 1983, when she began investigating tropical diseases and health care in rural Zaire. Since then she has worked in industry, government and CROs on a variety of therapeutic areas globally, including infectious, chronic and rare diseases. In 1997 she received her doctorate in Population...

Coleman K. Obasaju, M.D., Ph.D., senior medical director of Lilly Oncology is responsible for the strategic direction of oncology within the U.S. as well as the global division of oncology. Dr. Obasaju received his medical degree at the University College Hospital, Ibadan, Nigeria and pursued post-graduate training in clinical pharmacology and...

Lynn J. Okamoto, Pharm.D. is Senior Vice President of Health Economics and a Senior Research Scientist at United BioSource Corporation (UBC) in Lexington, MA. Dr. Okamoto leads the health economic and policy efforts in the US and interfaces with UBC’s European operations on global issues. She has extensive experience in global management, as well...

Rauha Tulkki-Wilke works at CRF Health, a company providing ePRO solutions to clinical trials, where she manages the development of new ePRO solutions for the pharmaceutical industry. Rauha has been with CRF Health since it was founded and has more than 10 years of experience with ePRO: developing new, patient-friendly ePRO solutions and...

As Vice President – Observational Research in PharmaNet’s Phase IV Development group, Ron has global responsibility for the design and implementation of non-interventional studies and patient registries. Having been involved with all aspects of drug discovery and development for over thirty years, Ron has focused during the past decade on...

Dr. Xiaofeng Zhou is a director in World Safety Strategy’s Epidemiology group at Pfizer Inc. She has 16 years of working experience with Pfizer in a wide variety of roles including the clinical development operation, post marketing drug safety and pharmacovigilance, clinical safety and risk management, and epidemiology. She has published and...